Living with Substance Use Disorder

Questions clinicians ask

What does the evidence show about GLP-1 receptor agonists and alcohol-related hospitalizations in people with alcohol use disorder?

The briefs describe emerging evidence that GLP-1 receptor agonist use is associated with fewer alcohol-related hospitalizations in people with alcohol use disorder. This suggests a potential role for incretin therapies in addiction care, but the evidence remains emerging and does not establish them as standard treatment for alcohol use disorder.

Can community pharmacies expand access to methadone treatment for opioid use disorder?

Pharmacy-based methadone treatment allows patients to obtain daily methadone from a local pharmacy rather than a dedicated treatment site. The model may reduce geographic and logistical barriers, extending access through existing community pharmacy infrastructure.

What does randomized evidence suggest about ketamine-assisted mindfulness-oriented recovery enhancement for opioid use disorder?

The covered randomized trial evaluates ketamine combined with mindfulness-oriented recovery enhancement as an adjunctive approach for opioid use disorder. The brief presents the combination as promising, while its applicability remains narrower than that of established medications for opioid use disorder and requires further confirmation.

Does cannabis provide effective long-term treatment for insomnia in patients with substance use concerns?

Although patients may report short-term sleep benefits, the covered evidence does not support cannabis as a reliable long-term insomnia treatment. Its effects on sleep can be inconsistent, and ongoing use may introduce tolerance, dependence, or worsening sleep-related problems.

Other conditions

• ADHD
• Allergy
• ALS
• Alzheimer's Disease
• Antimicrobial Resistance
• Anxiety
• Asthma
• Atopic Dermatitis
• Atrial Fibrillation
• Autism
• Breast Cancer
• Cervical Cancer